J0278
J0278 – Injection, amikacin sulfate, 100 mg · NDC Crosswalk & Billing Units
HCPCS Level II J-code · Medicare Part B drug billing
J-code
● 20 NDCs crosswalked per 100 MG $0.614/unit ASP+6%
📋 J0278 summary
J0278 is a HCPCS Level II J-code used to bill amikacin sulfate, 100 mg, billed per 100 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.
Code J0278
Billing unit 100 MG Payment limit $0.614/unit NDC-Crosswalk 20
Quarter Q3 2026
RxCUI Atlas Trace the drug concept →
⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.
🗂️ Key billing facts
HCPCS codeJ0278
DescriptorInjection, amikacin sulfate, 100 mg
Billing unit100 MG
Payment limit / unit$0.614
Est. ASP / unit$0.579 est.
Mapped NDCs20
Data periodQ3 2026
Last updated2026-08-20
💊 About Amikacin Injection DRUG GUIDE
Amikacin sulfate injection is used to treat serious infections caused by susceptible gram-negative bacteria, including Pseudomonas, E.
coli, Klebsiella, Serratia, Proteus, Providencia, and Acinetobacter species.
It is effective against bacterial septicemia (blood infection, including neonatal sepsis), serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis), skin and soft tissue, abdominal infections, burns, and postoperative infections.It is also used for serious complicated or recurrent urinary tract infections caused by these organisms, and may be used in certain staphylococcal infections, including in patients allergic to other antibiotics or when both gram-negative and gram-positive bacteria may be involved.
Amikacin is reserved for serious infections; it is not recommended for uncomplicated urinary tract infections unless other, less toxic antibiotics won't work.
Clinical overview from our editorial drug guide for Amikacin Injection. For billing reference, see the sections above.
🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026
📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$0.614
Est. ASP / unit
$0.579 est.
Est. after 2% sequester
$0.602
HCPCS dosage
100 MG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
Full HCPCS code details (official CMS record)
Long descriptionInjection, amikacin sulfate, 100 mg
CoverageC — Carrier/MAC judgment
Pricing indicator51 — Drug — priced under the ASP methodology
Type of service1 — Medical care
BETOS-2O1E
ASC payment group—
Action codeN — No maintenance this year
Effective date2006-01-01
Date added2006-01-01
Source: CMS HCPCS Level II code file (imported via admin).
🧮 Dosing & billing-units calculator HCPCS UNITS
One billing unit of J0278 = 100 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.
🔁 NDCs that bill under J0278 LEAST EXPENSIVE FIRST
20 NDCs map to J0278. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($0.614/unit) × that package's bill units.
| NDC (11-digit) | Drug | Labeler | Package | Strength | Bill units | Est. pay / pkg | NADAC / unit | Status | Source |
|---|---|---|---|---|---|---|---|---|---|
| 00641-6167-10 | Amikacin Sulfate 250 mg/mL INJECTION | Hikma | 10 VIAL, SINGLE-DOSE in 1 CARTON (0641-616... | 250 mg/mL | 50 | $30.70 | $2.297 | ● Active | CMS + PDAC |
| 23155-0290-41 | Amikacin Sulfate 250 mg/mL INJECTION, SOLUTION | Heritage | 10 VIAL, GLASS in 1 CARTON (23155-290-41)... | 250 mg/mL | 50 | $30.70 | $2.297 | ● Active | CMS ASP |
| 23155-0785-41 | Amikacin Sulfate 500 mg/2mL INJECTION, SOLUTION | Heritage | 10 VIAL, GLASS in 1 CARTON (23155-785-41)... | 500 mg/2mL | 50 | $30.70 | $2.297 | ● Active | CMS + PDAC |
| 25021-0173-02 | amikacin sulfate 250 mg/mL INJECTION, SOLUTION | Sagent | 10 VIAL in 1 CARTON (25021-173-02) / 2 mL... | 250 mg/mL | 50 | $30.70 | $2.297 | ● Active | CMS + PDAC |
| 63323-0815-02 | Amikacin Sulfate 250 mg/mL INJECTION, SOLUTION | Fresenius | 10 VIAL, SINGLE-DOSE in 1 CARTON (63323-81... | 250 mg/mL | 50 | $30.70 | $2.297 | ● Active | CMS ASP |
| 83301-0022-02 | Amikacin Sulfate 250 mg/mL INJECTION | Mullan | 10 VIAL, SINGLE-DOSE in 1 CARTON (83301-00... | 250 mg/mL | 50 | $30.70 | $2.297 | ● Active | CMS ASP |
| 00641-6166-10 | Amikacin Sulfate 250 mg/mL INJECTION | Hikma | 10 VIAL in 1 CARTON (0641-6166-10) / 4 mL... | 250 mg/mL | 100 | $61.40 | — | ● Active | CMS + PDAC |
| 23155-0290-42 | Amikacin Sulfate 250 mg/mL INJECTION, SOLUTION | Heritage | 10 VIAL, GLASS in 1 CARTON (23155-290-42)... | 250 mg/mL | 100 | $61.40 | — | ● Active | CMS ASP |
| 23155-0786-41 | Amikacin Sulfate 1 g/4mL INJECTION, SOLUTION | Heritage | 10 VIAL, GLASS in 1 CARTON (23155-786-41)... | 1 g/4mL | 100 | $61.40 | — | ● Active | CMS + PDAC |
| 25021-0173-04 | amikacin sulfate 250 mg/mL INJECTION, SOLUTION | Sagent | 10 VIAL in 1 CARTON (25021-173-04) / 4 mL... | 250 mg/mL | 100 | $61.40 | — | ● Active | CMS + PDAC |
| 63323-0815-04 | Amikacin Sulfate 250 mg/mL INJECTION, SOLUTION | Fresenius | 10 VIAL, SINGLE-DOSE in 1 CARTON (63323-81... | 250 mg/mL | 100 | $61.40 | — | ● Active | CMS ASP |
| 83301-0023-02 | Amikacin Sulfate 250 mg/mL INJECTION | Mullan | 10 VIAL, SINGLE-DOSE in 1 CARTON (83301-00... | 250 mg/mL | 100 | $61.40 | — | ● Active | CMS ASP |
| 62991-2002-01 | Amikacin Sulfate 1 g/g POWDER | LETCO | 5 g in 1 JAR (62991-2002-1) | 1 g/g | 10 | $6.14 | — | ● Active | PDAC |
| 62991-2002-02 | Amikacin Sulfate 1 g/g POWDER | LETCO | 25 g in 1 JAR (62991-2002-2) | 1 g/g | 10 | $6.14 | — | ● Active | PDAC |
| 38779-0295-03 | AMIKACIN SULFATE (U.S.P.) | Unknown | — | — | 10 | $6.14 | — | — | PDAC |
| 38779-0295-04 | AMIKACIN SULFATE (U.S.P.) | Unknown | — | — | 10 | $6.14 | — | — | PDAC |
| 38779-0295-05 | AMIKACIN SULFATE (U.S.P.) | Unknown | — | — | 10 | $6.14 | — | — | PDAC |
| 51927-2704-00 | AMIKACIN SULFATE (U.S.P.) | Unknown | — | — | 10 | $6.14 | — | — | PDAC |
| 00703-9032-03 | AMIKACIN SULFATE (S.D.V.) 250 MG/ML | Unknown | — | — | 2.5 | $1.54 | — | — | PDAC |
| 00703-9040-03 | AMIKACIN SULFATE (VIAL) 250 MG/ML | Unknown | — | — | 2.5 | $1.54 | — | — | PDAC |
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.
📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)
Period
Total Part B spend
$4.2K
Claims
865
Beneficiaries
411
Spend / beneficiary
$10.25
Spend / claim
$4.87
Trend by period
Where J0278 ranks among Part B drugs · 2026 (Q1) · neighbors ±5
Total spending — #713 of 824
#708
NEBUPENT(J2516)* J2516
$5.4K
#709
CALCIUM GLUCONATE-NA... J0612
$5.2K
#710
DELESTROGEN* J1380
$5.1K
#711
SYNOJOYNT, INJ., 1 M... J7331
$4.5K
#712
FUROSEMIDE(J1938) J1938
$4.2K
#713
AMIKACIN SULFATE J0278
$4.2K
#714
CLOFARABINE* J9027
$4.1K
#715
HEPARIN FLUSH J1642
$4K
#716
DIAZEPAM J3360
$3.9K
#717
COMIRNATY (5-11Y)* 91319
$3.8K
#718
ERAXIS J0348
$3.8K
Total claims — #389 of 824
#384
ORPHENADRINE CITRATE J2360
916
#385
PEMRYDI RTU J9324
903
#386
ENJAYMO J1302
892
#387
ASTAGRAF XL J7508
883
#388
PIPERACILLIN-TAZOBAC... J2543
873
#389
AMIKACIN SULFATE J0278
865
#390
LUMASON Q9950
846
#391
RELESE, PER SQ CM** Q4257
843
#392
LEUPROLIDE DEPOT* J1954
839
#393
VYLOY J1326
834
#394
DUOPA J7340
832
Top Medicare Part B drugs by the selected metric. Click any drug to open its J-code page. Source: CMS Medicare Quarterly Part B Spending by Drug.
Full breakdown by period (2)
| Period | Total spend | Beneficiaries | Claims | $/beneficiary | $/claim |
|---|---|---|---|---|---|
| 2026 (Q1) | $4.2K | 411 | 865 | $10.25 | $4.87 |
| 2025 (Q1-Q4) | $17K | 1,644 | 4,100 | $10.32 | $4.14 |
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.
📈 Medicare Part B claims detail CMS PSPS · 2024
Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$17.1K
Medicare paid
$13K
Submitted services
56,446
Denial rate
48.8%
Allowed / service
$0.59
Submitted charges
$349.9K
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.
🗺️ Where J0278 is utilized CMS · BY PROVIDER · 2024
Medicare Part B services for this code by the rendering provider's state — 8,560 services across 10 states & territories in 2024 (CMS reports include DC and U.S. territories). Switch to per 100k to compare states fairly regardless of population. Hover or tap a state for its top ZIP codes.
Hover or tap a state to see its numbers + top ZIP codes.
Per-capita = services ÷ 2023 state population × 100,000 (so high-population states aren't automatically "hotter"). Counts reflect the provider's location, not the patient's. Providers with fewer than 11 patients are hidden by CMS for privacy, so totals run low and per-100k can be noisy in small states — read this as relative geography, not exact counts. Source: CMS Medicare Physician & Other Practitioners — by Provider and Service, 2024.
📊 What bills under J0278
J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.
NDC products by ingredient
NDC products by labeler
🗃️ Data sources & freshness
Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Loaded
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)
20 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2026
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.
⚠️ Practical billing caveats
- A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
- Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
- Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
- Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
- The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
- Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.
❓ J0278 billing FAQ
What is HCPCS code J0278?
J0278 is a HCPCS Level II J-code used to bill Injection, amikacin sulfate, 100 mg under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J0278?
One unit of J0278 represents 100 MG. Report the number of units equal to the dose administered divided by 100 MG.
How many units of J0278 should I bill?
Divide the dose administered by the code's unit size (100 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J0278?
The Medicare Part B payment limit is $0.614 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $0.602 per unit. Payment limits are revised quarterly.
Which NDCs bill under J0278?
20 NDCs currently map to J0278 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J0278 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.